ProCE Banner Series

Mantle Cell Lymphoma: Novel Therapeutic Strategies Using the New Generation of BTK Inhibitors

Register now for this 1-hour interactive satellite symposium held in conjunction with the 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) in Houston, Texas to hear about how experts optimize and personalize the care of patients with MCL, including strategies used to select and sequence BTK inhibitor-based therapies, taking into consideration newly evolving treatment approaches, guideline recommendations and recent practice-changing clinical trial data. After the symposium, view the on-demand webcast and download the associated slideset for use in your clinic.

Independent Satellite Symposium on Mantle Cell Lymphoma: Novel Therapeutic Strategies Using the New Generation of BTK Inhibitors, preceding the Society of Hematologic Oncology 2023 Annual Meeting.

  ANCC
  | ACPE
  | AMA
Who Should Attend

This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other HCPs who treat patients with MCL.

All Events

Mantle Cell Lymphoma: Novel Therapeutic Strategies Using the New Generation of BTK Inhibitors

Past Events

September

08

2023

6:45 AM - 7:45 AM Central Time (CT)

In-personVirtual

George R Brown Convention Center, 1001 Avenida De Las Americas, Houston, Texas 77010

Topics

  • Welcome and Introduction
  • Mechanisms of action, pharmacokinetics, and pharmacodynamics of currently available BTK Inhibitors
  • Evidence-based Current and Emerging Roles of BTK Inhibitors in Treatment-Naive MCL
  • Role of BTK Inhibitors in Transplant-Eligible Patients with MCL
  • Selecting and Sequencing BTK Inhibitor Therapy in R/R MCL
  • Treatment options after BR + BTK Inhibitor Therapy
  • Practical Adverse Event Prevention, Mitigation and Management Strategies for Optimal Treatment Outcomes
  • Future of BTK Inhibitor therapy: Clinical Implications of Ongoing Studies and Application of New and Emerging Data
  • Spotlight of Key Abstracts at SOHO 2023
  • Real-World Case-Based Panel Discussions
  • Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Program Overview
This program will provide expert faculty perspectives on the optimal integration of BTK inhibitors into the management of MCL, and contextualize the evolving role of BTK inhibitors in the personalization of patient care using real-world clinical case studies to illustrate how to select and sequence BTK-inhibitor-based and non-BTK inhibitor-based treatments to maximize adherence, compliance, efficacy, safety and clinical outcomes.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Mantle cell lymphoma (MCL).

Target Audience
This educational program is intended for hematologists, medical oncologists, nurses, pharmacists, and other HCPs who treat patients with MCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal first-line treatment for patients with MCL who are not candidates for aggressive therapy
  • Develop BTKi-based therapeutic strategies for patients with newly diagnosed MCL who are eligible for ASCT
  • Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration guideline recommendations, new indications, and recent practice-changing clinical trial results
  • Manage treatment-related symptoms in patients with MCL receiving BTKi-based therapy to optimize adherence and clinical outcomes
  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Clinical Care Options, LLC. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.75 contact hour in the area of pharmacology. 

Continuing Pharmacy Education
Medical Learning Institute, Inc., designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-0000-23-077-L01-P

Type of Activity: Knowledge

Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 month with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity. 

Acknowledgement

This activity is developed with our educational partner, Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, Lilly, and Merck Sharp & Dohme LLC.

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191